Tyra Biosciences Raises $256M Cash, Eyes SURF302 and BEACH301 Data in 2026
Tyra Biosciences launched its “dabogratinib 3x3” strategy to advance 3 late-stage FGFR3 inhibitor trials in low-grade upper tract urothelial carcinoma, intermediate-risk NMIBC and achondroplasia, targeting SURF302 Phase 2 readout by 1H 2026 and BEACH301 interim data in 2H 2026. The company ended Q4 2025 with $256 million in cash and marketable securities, securing runway through at least 2027 after exiting metastatic bladder cancer to focus resources on its core indications.
1. Dabogratinib 3x3 Clinical Strategy
Tyra is executing its “dabogratinib 3x3” strategy to develop the first oral FGFR3 selective inhibitor in three potentially pivotal Phase 2 studies targeting low-grade upper tract urothelial carcinoma (SURF303), intermediate-risk non-muscle invasive bladder cancer (SURF302), and achondroplasia (BEACH301). SURF303 startup continues with first patient dosing expected in 2026, while SURF302 aims to report three-month complete response data by end-1H 2026 and BEACH301 will deliver safety sentinel cohort results in 2H 2026.
2. Financial Strength and Runway
The company closed Q4 2025 with $256.0 million in cash, cash equivalents and marketable securities, providing funding through at least 2027. Management refocused by exiting the metastatic bladder cancer program to allocate capital and operations toward its three core dabogratinib indications with the strongest risk-adjusted potential.
3. Trial Progress and Next Milestones
Over 100 participants have been dosed across trials, reinforcing confidence in dabogratinib's efficacy and tolerability for once-daily dosing. Interim readouts from SURF302 and BEACH301 will inform pivotal trial designs, while translational data from the completed SURF301 study have guided dose selection for upcoming studies.